Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–51.
Google Scholar
Wang M, Zhao JH, Tang MX, Li M, Zhao H, Li ZY, et al. Cell death modalities in therapy of melanoma. Int J Mol Sci. 2025;26.
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.
Google Scholar
Tummers B, Green DR. Caspase-8: regulating life and death. Immunol Rev. 2017;277:76–89.
Google Scholar
Kashkar H, Pasparakis M. Cell-death networks. Mol Cell. 2025;85:3890–e1.
Google Scholar
Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187:235–56.
Google Scholar
Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517:311–20.
Google Scholar
Pop C, Oberst A, Drag M, Van Raam BJ, Riedl SJ, Green DR, et al. FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J. 2011;433:447–57.
Google Scholar
Fox JL, Hughes MA, Meng X, Sarnowska NA, Powley IR, Jukes-Jones R, et al. Cryo-EM structural analysis of FADD:Caspase-8 complexes defines the catalytic dimer architecture for co-ordinated control of cell fate. Nat Commun. 2021;12:819.
Google Scholar
Newton, Wickliffe K, Maltzman KE, Dugger A, Reyes DL, Jr J, et al. cFLIP suppresses caspase-1- and MLKL-independent perinatal lethality driven by auto-processing impaired caspase-8 D387A. Cell Death Differ. 2025.
Shaw JJP, Guy C, Tummers B, Green DR. FLIP(L) permits apoptotic and inflammatory signaling and inhibits necroptosis in mice without Caspase-8 oligomerization. Proc Natl Acad Sci USA. 2025;122:e2415992122.
Google Scholar
Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–90.
Google Scholar
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70.
Google Scholar
Helson L, Green S, Carswell E, Old LJ. Effect of tumour necrosis factor on cultured human melanoma cells. Nature. 1975;258:731–2.
Google Scholar
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.
Google Scholar
Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013;3:881–91.
Google Scholar
Daoud M, Broxtermann PN, Schorn F, Werthenbach JP, Seeger JM, Schiffmann LM, et al. XIAP promotes melanoma growth by inducing tumour neutrophil infiltration. EMBO Rep. 2022;23:e53608.
Google Scholar
Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, Zigrino P, et al. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res. 2010;70:1825–34.
Google Scholar
Steinkamp J, Mersch N, Kashkar H, Zigrino P. Targeting XIAP and EGFR as an Approach for Treating Melanoma. Exp Dermatol. 2025;34:e70144.
Google Scholar
Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, et al. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood. 2007;109:3982–8.
Google Scholar
Kashkar H, Kronke M, Jurgensmeier JM. Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ. 2002;9:750–7.
Google Scholar
Fritsch M, Gunther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683–7.
Google Scholar
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
Google Scholar
Schorn F, Werthenbach JP, Hoffmann M, Daoud M, Stachelscheid J, Schiffmann LM, et al. cIAPs control RIPK1 kinase activity-dependent and -independent cell death and tissue inflammation. EMBO J. 2023;42:e113614.
Google Scholar
Gunther SD, Fritsch M, Seeger JM, Schiffmann LM, Snipas SJ, Coutelle M, et al. Cytosolic Gram-negative bacteria prevent apoptosis by inhibition of effector caspases through lipopolysaccharide. Nat Microbiol. 2020;5:354–67.
Google Scholar
Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397–411.
Google Scholar
Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Piekarek M, et al. Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol Med. 2014;6:624–39.
Google Scholar
Schiffmann LM, Werthenbach JP, Heintges-Kleinhofer F, Seeger JM, Fritsch M, Gunther SD, et al. Mitochondrial respiration controls neoangiogenesis during wound healing and tumour growth. Nat Commun. 2020;11:3653.
Google Scholar
Witt A, Seeger JM, Coutelle O, Zigrino P, Broxtermann P, Andree M, et al. IAP antagonization promotes inflammatory destruction of vascular endothelium. EMBO Rep. 2015;16:719–27.
Google Scholar
Kylaniemi MK, Kaukonen R, Myllyviita J, Rasool O, Lahesmaa R. The regulation and role of c-FLIP in human Th cell differentiation. PLoS One. 2014;9:e102022.
Google Scholar
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–81.
Google Scholar
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682–93.
Google Scholar
Laurien L, Nagata M, Schunke H, Delanghe T, Wiederstein JL, Kumari S, et al. Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nat Commun. 2020;11:1747.
Google Scholar
Meng H, Liu Z, Li X, Wang H, Jin T, Wu G, et al. Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis. Proc Natl Acad Sci USA. 2018;115:E2001–E9.
Google Scholar
Newton K. Multitasking kinase RIPK1 regulates cell death and inflammation. Cold Spring Harb Perspect Biol. 2020;12.
Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343:1357–60.
Google Scholar
Varfolomeev E, Vucic D. RIP1 post-translational modifications. Biochem J. 2022;479:929–51.
Google Scholar
Geserick P, Wang J, Schilling R, Horn S, Harris PA, Bertin J, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015;6:e1884.
Google Scholar
Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell. 2014;157:1189–202.
Google Scholar
Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C, et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci USA. 2014;111:7753–8.
Google Scholar
Rickard JA, O’Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell. 2014;157:1175–88.
Google Scholar
Yu X, Lu D, Qi X, Paudel RR, Lin H, Holloman BL, et al. Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024;15:10683.
Google Scholar
Tian F, Lu JJ, Wang L, Li L, Yang J, Li Y, et al. Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease. Clin Exp Dermatol. 2012;37:259–65.
Google Scholar
Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene. 2008;27:3211–20.
Google Scholar
Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, et al. Effect of a Smac mimetic (TL32711, Birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use. Clin Cancer Res. 2016;22:1000–10.
Google Scholar
Ivanisenko NV, Seyrek K, Hillert-Richter LK, Konig C, Espe J, Bose K, et al. Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks. Trends Cancer. 2022;8:190–209.
Google Scholar
Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariame AF, Touriol C, et al. Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 2015;75:2619–28.
Google Scholar
Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24:1697–703.
Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Google Scholar
Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol. 2021;17:213–23.
Google Scholar
Virazels M, Lusque A, Brayer S, Genais M, Dufau C, Milhes J, et al. TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFalpha clinical study. Int J Cancer. 2025;157:534–48.
Google Scholar
van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol. 2023;23:289–303.
Google Scholar
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Segui B. The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019;10:1818.
Google Scholar
Freeman AJ, Kearney CJ, Silke J, Oliaro J. Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends Immunol. 2021;42:1128–42.
Google Scholar
Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012;34:176–84.
Google Scholar
